Currently out of the existing stock ratings of Kyle Mikson, 107 are a BUY (91.45%), 10 are a HOLD (8.55%).

Kyle Mikson

Work Performance Price Targets & Ratings Chart

Analyst Kyle Mikson, currently employed at CANACCORD, carries an average stock price target met ratio of 21.58% that have a potential upside of 19.39% achieved within 55 days.

Kyle Mikson’s has documented 229 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on CSTL, Castle Biosciences at 29-Oct-2024.

Wall Street Analyst Kyle Mikson

Analyst best performing recommendations are on TTOO (T2 BIOSYSTMS).
The best stock recommendation documented was for TTOO (T2 BIOSYSTMS) at 4/29/2024. The price target of $3 was fulfilled within 1 day with a profit of $0.16 (5.63%) receiving and performance score of 56.34.

Average potential price target upside

BDSX Biodesix  ILMN Illumina LUCD Lucid Diagnostics NTRA Natera PACB Pacific Biosciences of California QSI QuantumSi XGN Exagen CSTL Castle Biosciences EXAS EXACT Sciences GH Guardant Health NSTG NanoString Technologies QTRX Quanterix Corp TTOO T2 Biosystms SLGC Somalogic TX Ternium SA ADR AKYA Akoya Biosciences TXG 10X Genomics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3.5

$2.2 (169.23%)

$3.5

8 months 1 days ago
(04-Mar-2024)

0/8 (0%)

$1.95 (125.81%)

Hold

$11

2 years 5 months 24 days ago
(12-May-2022)

0/2 (0%)

$4.47 (68.45%)

Buy

$31

2 years 6 months 16 days ago
(20-Apr-2022)

3/5 (60%)

$7.27 (30.64%)

31

Buy

$17

2 years 6 months 18 days ago
(18-Apr-2022)

0/2 (0%)

$11.65 (148.93%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kyle Mikson is most bullish on?

Potential upside of $25.84 has been obtained for NTRA (NATERA)

Which stock is Kyle Mikson is most reserved on?

Potential downside of $0.56 has been obtained for PACB (PACIFIC BIOSCIENCES OF CALIFORNIA)

What Year was the first public recommendation made by Kyle Mikson?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?